| 徐南飞 陈晓雷 马志伟 冯 涛.阿托伐他汀治疗冠心病合并脑梗死的临床研究[J].,2014,14(35):6913-6915 |
| 阿托伐他汀治疗冠心病合并脑梗死的临床研究 |
| Clinical Research of Atorvastatin Combined Amlodipine Combined inTreatment of Coronary Heart Disease and Cerebral Infarction |
| |
| DOI： |
| 中文关键词: 阿托伐他汀 苯磺酸氨氯地平 冠心病 脑梗死 |
| 英文关键词: Atorvastatin Amlodipine Besylate Tablet Coronary artery disease Cerebral infarction |
| 基金项目:教育部留学回国人员科研启动基金（教外司留（ 2011）1 568 号） |
|
| 摘要点击次数: 721 |
| 全文下载次数: 910 |
| 中文摘要: |
| 目的： 研究阿托伐他汀联合苯磺酸氨氯地平治疗 冠心病合并脑梗死的临床效果。 方法： 从 2011 年 1 月 到 2013 年 1 月 ，在我
院共有 96 例 病患被诊断为冠心病合并脑梗死。 以数字法随机分成观察组（ 48 例）和对照组（ 48 例）。 对照组每天口服苯磺酸氨氯
地平， 观察组在对照组的基础上口服阿托伐他汀钙片 。 对比两组疗效及病患血脂水平。 结果： 观察组疗效为 优者占 比 62.50 %
（ 30/48）， 优良率为 91 .67 %（ 44/48）， 均显著高于对照组的 39.58 %（ 19/48）， 75.00 %（ 36/48）， 差异均有统计学意义（均 P＜ 0.05）； 观
察组治疗后 TC （ 4.74± 1 .20）mmol/L， 显著性低于对照组 （ 5.22± 1 .15）mmol/L， TG （ 1 .06± 0.30）mmol/L， 显著性低于对照组
（ 1 .51± 0.28）mmol/L， LDL-C（ 3.19± 0.51）mmol/L， 显著性低于对照组（ 3.87± 0.25）mmol/L，上述差异均有统计学意义（ P＜ 0.05）。
结论： 阿托伐他汀联合苯磺酸氨氯地平治疗 冠心病合并脑梗死， 不仅可明 显提升治疗效果， 还可减少病患的并发症的发生。 方便
安全，值得临床推荐。 |
| 英文摘要: |
| Objective:To study the therapeutic effect of combined atorvastatin amlodipine besylate in treatment of coronary heart
disease and cerebral infarction.Methods:96 patients in our hospital who were diagnosed coronary heart disease and cerebral infarction
from January 2011 to January 201 3 were selected and were digitally randomly divided into observation group (48 cases) and control
group (48 cases) . The control group was treated with amlodipine besylate daily, and the observation group was treated with atorvastatin
calcium on the basis of the control group. The therapeutic effect and the blood lipid levels of two groups of patients was compared.Results:The patients of the observation group were excellent accounting for 62.50% (30/48), good for 91.67% (44/48), which were
significantly higher than that of control group, which were 39.58% (19/48),75.00% (36/48), respectively. The differences was statistically
significant (P<0.05). TC in observation group was (4.74± 1 .20) mmol/L, which was significantly lower than that of control group (5.22±
1 .1 5) mmol/L, and TG was (1 .06± 0.30) mmol/L, LDL-C was (3.19± 0.51) mmol/L, which were significantly lower than control group’ s
(1 .51 ± 0.28) mmol/L and (3.87 ± 0.25) mmol/L. Differences above all showed statistically significant (P<0.05).Conclusion:Atorvastatin combined amlodipine in treatment of coronary heart disease and cerebral infarction can significantly improve the therapeutic
effect, also can reduce the occurrence of complications in patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
